TriSalus Life Sciences (NASDAQ:TLSI) is a pioneering biotechnology firm committed to transforming the treatment of solid tumors through integrated therapeutic and drug delivery solutions. Focusing on innovative research and development, TriSalus is dedicated to advancing technologies that enhance the delivery of immunotherapies and drugs directly to the site of disease, especially targeting liver and pancreatic cancers. The company's projects include developing proprietary Pressure-Enabled Drug Delivery (PEDD) technology and SD-101, an immunotherapy agent, aiming to improve outcomes for patients battling these hard-to-treat cancers. TriSalus's objective is to overcome the limitations of current treatments by enhancing drug concentrations at the tumor site, thereby improving therapeutic efficacy and patient survival rates.